Aldehyde dehydrogenase 18 family, member A1


Delta-1-pyrroline-5-carboxylate synthetase is an enzyme that in humans is encoded by the ALDH18A1 gene.
This gene is a member of the aldehyde dehydrogenase family and encodes a bifunctional ATP- and NADPH-dependent mitochondrial enzyme with both gamma-glutamyl kinase and gamma-glutamyl phosphate reductase activities. The encoded protein catalyzes the reduction of glutamate to delta1-pyrroline-5-carboxylate, a critical step in the de novo biosynthesis of proline, ornithine and arginine. Mutations in this gene lead to hyperammonemia, hypoornithinemia, hypocitrullinemia, hypoargininemia and hypoprolinemia and may be associated with neurodegeneration, cataracts and connective tissue diseases. Alternatively spliced transcript variants, encoding different isoforms, have been described for this gene.

Structure

P5CS consists of two domains: gamma-glutamyl kinase and gamma-glutamyl phosphate reductase, each of which are used to complete the two steps to create ornithine and proline. The gamma-glutamyl kinase domain employs a 367-residue chain that folds into an N-terminal amino acid kinase domain, responsible for catalysis and proline inhibition, and a C-terminal PUA RNA binding domain. This enzyme is also a tetramer formed by two dimers, and the monomers and dimers are assembled in a manner that allows the amino acid kinase active pockets to be alternatively oriented in the tetramer. The short version and the long version of PC5S are two isoforms of this enzyme which differs by the addition of two amino acids in the long form and with an extra 6-bp insert following bp+711. This slight difference creates a dramatic difference in how they are affected by the inhibition of ornithine. The ALDH18A1 gene spans 15 kb, is mapped on 10q24.3, and has an exon count of 18.

Function

P5CS catalyzes the phosphorylation- and reduction-conversion of glutamate to Delta-1-pyrroline-5-carboxylate. This occurs through a process in which glutamate is converted into gamma-glutamyl phosphate in the gamma-glutamyl kinase domain and then the gamma-glutamyl phosphate is the made into gamma-glutamic semi-aldehyde in the gamma-glutamyl phosphate reductase domain. The gamma-glutamic semi-aldehyde is in tautomeric equilibrium with P5C and it is the obligatory intermediate in the interconversions of proline, ornithine, and glutamate. The two isoforms are both involved in different activities as well. The short version has high activity in the gut and is a main participant in the biosynthesis of arginine. The long version of PC5S is expressed in various tissues and is significant for its ability to synthesize proline from glutamate. Also, the short version is inhibited by ornithine, whereas the long version is insensitive to the amino acid.

Clinical significance

Ornithine and/or arginine are key intermediates for the synthesis of urea, creatine, nitric oxide, polyamines, and protein; while proline is a major component of the connective tissue
proteins, collagen and elastin. Because all three of these amino acids are a part of very significant processes, the presence of P5CS becomes an important regulator which makes sure that none of these three become deficient. Therefore, a lack of P5CS, due to mutations in the ALDH18A1 gene, often leads to neurodegeneration, joint laxity, skin hyperelasticity, bilateral sub capsular cataracts, and a plethora of other complications associated with impaired proline and ornithine synthesis.

Interactions

P5CS has been seen to interact with: